RxDoctor Payments Data

Misty McGough

Family · Moultrie, GANPI 1942884275

Payments from drug & device makers

$6,077in general payments, 2019–2025

Across 351 payments — averaging $17.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Johnson & Johnson$731
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$451
  • Daiichi Sankyo Inc.$371
  • Evoke Pharma, Inc.$363
  • Madrigal Pharmaceuticals$359
  • plus $2K from 27 others

What the payments were for

  • Food & beverage$5,91497%
  • Education$1633%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,077 in reported general payments places this provider in the 95th percentile of 6,258 family providers in Georgia.

See all family providers in Georgia

Medicare billing

Part B allowed, 2024
$14,605
Medicare patients
161
Services billed
208

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase81$306,305
ZenpepLipase/Protease/Amylase19$140,581
LinzessLinaclotide163$127,323
Humira(Cf) PenAdalimumab13$102,427
XifaxanRifaximin18$57,245
RezdiffraResmetirom15$56,216
IbsrelaTenapanor Hcl19$44,616
GimotiMetoclopramide Hcl15$32,216
Dexlansoprazole DrDexlansoprazole105$26,875
ClenpiqSod Picosulf/Mag Ox/Citric Ac113$19,419
MotegrityPrucalopride Succinate19$18,962
Lubiprostone115$11,086
Dicyclomine Hcl425$8,195
TrulancePlecanatide11$7,396
Sucralfate159$6,817

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$1,628$433,628244 claims
Aimmune Therapeutics, Inc.Zenpep$132$140,58119 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance$451$64,64129 claims
Madrigal PharmaceuticalsRezdiffra$359$56,21615 claims
Ardelyx, Inc.Ibsrela$34$44,61619 claims
Evoke Pharma, Inc.Gimoti$363$32,21615 claims
Takeda Pharmaceuticals U.S.A., Inc.Motegrity, Dexilant$276$22,77830 claims
Ferring Pharmaceuticals Inc.Clenpiq$160$19,419113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,258 family providers in Georgia.

Other family in Moultrie

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →